534个药品通过2025年国家医保药品目录初步形式审查

Core Insights - The National Healthcare Security Administration (NHSA) of China has publicly announced the preliminary review results for the 2025 National Medical Insurance Drug List, indicating a significant increase in the number of drug names passing the initial review compared to 2024 [1] Group 1: Drug List Review - A total of 718 submissions for the basic medical insurance drug list were received, involving 633 drug names, with 534 passing the preliminary review [1] - For the 2024 review, only 249 drug names passed, showing a notable increase in successful submissions this year [1] Group 2: Commercial Insurance Drug List - The NHSA has introduced a new commercial insurance innovative drug list, which was submitted concurrently with the basic medical insurance list [1] - There were 141 submissions for the commercial insurance innovative drug list, with 121 drug names passing the preliminary review [1] Group 3: Review Process Clarification - The NHSA emphasized that passing the preliminary review only indicates compliance with submission conditions and does not guarantee inclusion in the final drug lists [1] - The drugs that pass the preliminary review will still undergo public scrutiny before being officially included in the basic medical insurance or commercial insurance innovative drug lists [1]